Aldeyra Therapeutics (ALDX) Net Cash Flow (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Net Cash Flow came in at -$5.0 million in Q1 2026, down 20.65% YoY from -$6.4 million in Q1 2025, and down 147.09% on a QoQ basis from $10.7 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Net Cash Flow (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Net Cash Flow data on file, last reported at -$5.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 20.65% year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.7 million (up 128.1% YoY) and the FY2025 annual result came in at $15.5 million, up 117.57% from the prior year.
- Net Cash Flow fell to -$5.0 million in Q1 2026, from $10.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $20.6 million in Q1 2023 to a low of -$70.9 million in Q1 2022.
- A 5-year average of -$9.7 million and a median of -$5.0 million in 2026 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow tumbled 2555.53% — and 2025, when it surged 722.04%.
- Tracing ALDX's Net Cash Flow over 5 years: stood at $15.8 million in 2022, then plunged by 103.25% to -$511872.0 in 2023, then plunged by 2555.53% to -$13.6 million in 2024, then surged by 178.72% to $10.7 million in 2025, then sank by 147.09% to -$5.0 million in 2026.
- The last three Net Cash Flow figures came in at -$5.0 million (Q1 2026), $10.7 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 225.59 Mn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | -19.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.91 Mn |
| Jun 30, 2026 | -19.91 Mn |
| Mar 31, 2026 | -5.04 Mn |
| Mar 31, 2026 | -5.04 Mn |
| Dec 31, 2025 | 10.70 Mn |
| Dec 31, 2025 | 10.70 Mn |
| Sep 30, 2025 | 18.10 Mn |
| Sep 30, 2025 | 18.10 Mn |
| Jun 30, 2025 | -9.11 Mn |
| Jun 30, 2025 | -9.11 Mn |
| Mar 31, 2025 | -4.18 Mn |
| Mar 31, 2025 | -4.18 Mn |
| Dec 31, 2024 | -13.59 Mn |
| Dec 31, 2024 | -13.59 Mn |
| Sep 30, 2024 | -2.91 Mn |
| Sep 30, 2024 | -2.91 Mn |
| Jun 30, 2024 | -31.46 Mn |
| Jun 30, 2024 | -31.46 Mn |
| Mar 31, 2024 | -40.33 Mn |
| Mar 31, 2024 | -40.33 Mn |